Displaying items by tag: Concurrent Session

2:15 pm–3:15 pm Saturday, September 7

Engaging Pediatric Oncology Nurses in Multi-Site Clinical Trials (C234)

coglogo Pediatric oncology nurses at 16 Magnet^® hospitals are engaged in a three year, a multi-site research study funded by the American Nurses Credentialing Center. This study is evaluating the effectiveness of two parent education discharge support strategies (PEDSS–symptom management vs. PEDSS–dealing with diagnosis) for parents of children newly diagnosed with cancer.

Speaker:: Marilyn Hockenberry, PhD RN PNP FAAN
Megan Arthur, BS
Emily Daut, MSN RN PPCNP-BC CPHON^®
Donna Hancock, MSN RN
Micah Skeens, PhD RN CPNP
Katherine Trimble, MSN CPNP CPHON^®
Monica Wallin, MSN RN CPHON^®
CNE Hours: 1

11:30 am–12:30 pm Saturday, September 7

Beyond the Cure: The Children’s Oncology Group Uses Evidence and Clinical Trials to Study Late Effects in Childhood Cancer Survivors (C229)

coglogo Childhood cancer survivors are living longer than ever before, with overall survival rates exceeding 80%. As a result, survivors are living with chronic late health effects related to their curative treatments. Late effects may include second malignancies, endocrinopathies, cardiomyopathy, infertility, pulmonary function deficits, renal/ocular/auditory disorders, neurocognitive deficits, and metabolic syndrome.

Speaker:: Eleanor Hendershot, MN BScN RN(EC)
CNE Hours: 1
RX Hours: 0.17

4:15–5:15 pm Friday, September 6

Shaping the Future with Clinical Trials: Empowered Nurses a Key to their Success (C223)

coglogo In pediatric oncology, clinical trials are conducted to improve survival rates, understand disease biology, and prevent and/or improve management of treatment-related acute and long-term side effects. The majority of children newly diagnosed with cancer in North America are treated on Children’s Oncology Group (COG) clinical trials. In the last 50 years, clinical trials in pediatric oncology have increased the overall 5-year survival rate from under 10% to over 80% today.

Speaker:: Micah Skeens, PhD RN CPNP
Katy Tomlinson, BSN RN
CNE Hours: 1

11:30 am–12:30 pm Friday, September 6

Livers, Kidneys, and Germ Cells – Oh My! Helping Nurses Understand the Children’s Oncology Group Approach to Unique Childhood Cancers (C217)

coglogo Liver, kidney (renal cell carcinoma), and germ cell tumors are rare cancer diagnoses in children and adolescents (Ward E., et al 2014). Enrollment on clinical trials is essential for the continued improvements in outcomes for children with cancer; however, uncommon childhood malignancies make the conduct of these trials a significant challenge (Czauderna P., et al 2016).

Speaker:: Micah Skeens, PhD RN CPNP
Denise Mills, RN(EC) MN NP CPHON^®
CNE Hours: 1

5:00–6:00 pm Thursday, September 5

Infant ALL: Rearranged for the Big Screen! Providing Care on COG AALL15P1, Nurses in a Leading Role! (C211)

coglogo Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, with 5-year overall survival rates exceeding 90% (Hunger, Lu, Devidas, Camitta, Gaynon, Winick, 2012). Unfortunately, infants with ALL are an exception to the improving survival trends and remain one of the most challenging populations in pediatric hematology/oncology (Kotecha, Gottardo, Kees, Cole, 2014).

Speaker:: Holly Kubaney, MSN PPCNP-BC CPHON^®
Anne Raines, MSN RN CPHON^®
CNE Hours: 1
RX Hours: 0.25

3:45–4:45 pm Thursday, September 5

Navigating 131I-MIBG and CAR T 19, in COG trials ANBL1531 and AALL1721: Sharing Care and Strategies for Success (C205)

coglogo The Children’s Oncology Group (COG) is committed to improving outcomes for pediatric oncology patients with the high-risk disease through clinical trials. Despite tremendous advancements in pediatric oncology treatment, survival in two patient populations remains inferior. Patients with high-risk neuroblastoma have a projected 3-year event-free survival of 73% (Park et al., 2016), and patients with precursor B lineage acute lymphoblastic leukemia with positive minimal residual disease at the end of consolidation have a projected 5-year disease-free survival of 39% (Borowitz et al., 2015).

Speaker:: Diane Baniewicz, MSN CPNP
Jeneane Sullivan, MSN RN CPON^®
Sue Zupanec, MN NP Pediatrics
CNE Hours: 1

2:15–3:15 pm Saturday, September 7

Patient and Family Education for Newly Diagnosed Pediatric/Adolescent/Young Adult Oncology Patients: Development of an Interdisciplinary Education Roadmap (233)

The education of newly diagnosed pediatric, adolescent, and young adult (AYA) oncology patients and their caregivers is a critical component of successful oncology care. Patient education affects patient safety, timeliness and cost of care, treatment and research compliance, and the patient and family experience. Successful delivery of patient education is challenging because of the complex medical content conveyed, logistical challenges of healthcare delivery across multidisciplinary service lines (e.g., inpatient vs. outpatient with providers from medicine, nursing, psychology, social work), and patient and family variables that impact health and access to care (e.g., language, health literacy, coping skills, family and community support, insurance, financial stability, housing, transportation).

Speaker:: Katy Tomlinson, BSN RN
Sarah Dobrozsi, MD MS
CNE Hours: 1

2:15–3:15 pm Saturday, September 7

Get Out of Here! Surgical Resection of Solid Tumors in Pediatric Patients (232)

The purpose of this session is to educate our audience on 3 types of solid abdominal tumors and show how surgery is pivotal to increasing survival and decreasing the amount of systemic therapy needed. As APHON nurses, we frequently educate ourselves on chemotherapy, radiation therapy, and immunotherapy. The role of surgery is crucial to the treatment and survival of pediatric oncology patients.

Speaker:: Rachel Glincher, MSN RN CPNP-AC CPN CPHON^®
Mariel Marrano, MSN FNP-BC
CNE Hours: 1

2:15–3:15 pm Saturday, September 7

HCT & Gene Therapy in the Treatment of Inherited Metabolic Disorders (231)

Inherited metabolic disorders (IMDs) are a diverse group of diseases caused by genetic mutations that result in potentially lethal enzymatic abnormalities. Some IMDs such as adrenoleukodystrophy and mucopolysaccharidosis can be diagnosed by routine newborn screen, while others will present later in life when symptoms appear.

Speaker:: Victoria Szenes, MS RN CPNP
CNE Hours: 1

2:15–3:15 pm Saturday, September 7

A New Tool for Documenting the Child's Report of Cancer Treatment Toxicity (230)

The National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) is the standard lexicon for grading adverse events (AEs) in oncology trials. Children with cancer experience significant numbers of subjective AEs such as fatigue, pain, or sadness. The current standard is that AEs are reported only by clinicians, even though 30% of the 790 CTCAE items are subjective.

Speaker:: Pamela Hinds, PhD RN FAAN
Judy Bosi, BS CCRP
Catriona Mowbray, PhD BSN RN
Janice Withycombe, PhD RN MN CCRP
CNE Hours: 1